Literature DB >> 9102061

Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry.

P Ballanti1, S Minisola, M T Pacitti, L Scarnecchia, R Rosso, G F Mazzuoli, E Bonucci.   

Abstract

Tartrate-resistant acid phosphatase (TRAP) activity is regarded as an important cytochemical marker of osteoclasts; its concentration in serum is utilized as a biochemical marker of osteoclast function and degree of bone resorption. This study was carried out to assess the sensitivity of TRAP activity both as a cytochemical marker in histological sections and as a biochemical marker in serum in comparison with the standardized histomorphometric variables of osteoclasts. To this end we investigated 24 patients (21 women, 3 men; 60 +/- 17 years of age) affected with various metabolic bone diseases. Osteoclast surface (OcS/BS) and osteoclast number (OcN/BS) were evaluated by standardized histomorphometry in iliac crest biopsies. On the basis of TRAP cytochemical activity, TRAP-positive osteoclast surface (TRAP + OcS/BS) and number (TRAP + OcN/BS) were measured. TRAP-positive cells adjacent to bone and showing one nucleus or no nuclei at all in the plane of section were included in the counts as osteoclasts. Serum TRAP activity was determined by spectrophotometric assay. Values of OcS/BS and OcN/BS were much lower than those of TRAP + OcS/BS (-50%) and TRAP + OcN/BS (-60%), respectively. Correlations between OcS/BS and TRAP + OcS/BS, and between OcN/BS and TRAP + OcN/BS, were highly significant. Serum TRAP was significantly correlated with OcS/BS, OcN/BS, and TRAP + OcN/BS. These correlations, however, were rather low. Moreover, serum TRAP did not correlate with TRAP + OcS/BS. From these results, the conclusion can be drawn that while TRAP activity is confirmed as a valid cytochemical marker for identification of osteoclasts, serum TRAP activity is an osteoclastic marker of weak sensitivity. This may be due to known factors, such as synthesis of the enzyme not being unique to osteoclasts, enzyme instability, and the presence of inhibitors in serum. Mononucleated osteoclasts do not significantly influence the serum enzyme levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9102061     DOI: 10.1007/bf01623458

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  18 in total

1.  Paramyxovirus-like nuclear inclusions identical to those of Paget's disease of bone detected in giant cells of primary oxalosis.

Authors:  P Bianco; G Silvestrini; P Ballanti; E Bonucci
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Calcitonin, osteoclasts, and bone turnover.

Authors:  S Wallach; J B Carstens; L V Avioli
Journal:  Calcif Tissue Int       Date:  1990-12       Impact factor: 4.333

3.  Purification and characterization of human bone tartrate-resistant acid phosphatase.

Authors:  S H Allen; P R Nuttleman; C M Ketcham; R M Roberts
Journal:  J Bone Miner Res       Date:  1989-02       Impact factor: 6.741

4.  Expression of tartrate-resistant acid phosphatase in bone marrow macrophages.

Authors:  P Bianco; M Costantini; L C Dearden; E Bonucci
Journal:  Basic Appl Histochem       Date:  1987

5.  Kinetic and cytochemical identification of osteoclast precursors and their differentiation into multinucleated osteoclasts.

Authors:  R Baron; L Neff; P Tran Van; J R Nefussi; A Vignery
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

6.  Tartrate-resistant acid phosphatase as a marker of bone resorption.

Authors:  C P Price; A Kirwan; C Vader
Journal:  Clin Chem       Date:  1995-05       Impact factor: 8.327

7.  When is it an osteoclast?

Authors:  M Kaye
Journal:  J Clin Pathol       Date:  1984-04       Impact factor: 3.411

8.  Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover.

Authors:  L Scarnecchia; S Minisola; M T Pacitti; V Carnevale; E Romagnoli; R Rosso; G F Mazzuoli
Journal:  Scand J Clin Lab Invest       Date:  1991-10       Impact factor: 1.713

Review 9.  Biochemical markers of bone turnover.

Authors:  P D Delmas
Journal:  J Bone Miner Res       Date:  1993-12       Impact factor: 6.741

10.  Sensitivity of bone histomorphometry in the diagnosis of metabolic bone diseases.

Authors:  P Ballanti; C Della Rocca; E Bonucci; S Milani; V Lo Cascio; B Imbimbo
Journal:  Pathol Res Pract       Date:  1989-11       Impact factor: 3.250

View more
  31 in total

1.  Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.

Authors:  Sofia Bougioukli; Ashish Jain; Osamu Sugiyama; Brian A Tinsley; Amy H Tang; Matthew H Tan; Douglas J Adams; Paul J Kostenuik; Jay R Lieberman
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

2.  Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.

Authors:  Kazuyo Takeda; Rewati Adhikari; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

3.  Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation.

Authors:  Julia N Cheng; Jennifer B Frye; Susan A Whitman; Janet L Funk
Journal:  Clin Exp Metastasis       Date:  2019-12-20       Impact factor: 5.150

4.  Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.

Authors:  Yongfen Min; Xiubao Ren; David B Vaught; Jin Chen; Edwin Donnelly; Conor C Lynch; P Charles Lin
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

5.  ATRAID regulates the action of nitrogen-containing bisphosphonates on bone.

Authors:  Lauren E Surface; Damon T Burrow; Jinmei Li; Jiwoong Park; Sandeep Kumar; Cheng Lyu; Niki Song; Zhou Yu; Abbhirami Rajagopal; Yangjin Bae; Brendan H Lee; Steven Mumm; Charles C Gu; Jonathan C Baker; Mahshid Mohseni; Melissa Sum; Margaret Huskey; Shenghui Duan; Vinieth N Bijanki; Roberto Civitelli; Michael J Gardner; Chris M McAndrew; William M Ricci; Christina A Gurnett; Kathryn Diemer; Fei Wan; Christina L Costantino; Kristen M Shannon; Noopur Raje; Thomas B Dodson; Daniel A Haber; Jan E Carette; Malini Varadarajan; Thijn R Brummelkamp; Kivanc Birsoy; David M Sabatini; Gabe Haller; Timothy R Peterson
Journal:  Sci Transl Med       Date:  2020-05-20       Impact factor: 17.956

6.  Kynurenine, a Tryptophan Metabolite That Accumulates With Age, Induces Bone Loss.

Authors:  Mona El Refaey; Meghan E McGee-Lawrence; Sadanand Fulzele; Eileen J Kennedy; Wendy B Bollag; Mohammed Elsalanty; Qing Zhong; Ke-Hong Ding; Nathaniel G Bendzunas; Xing-Ming Shi; Jianrui Xu; William D Hill; Maribeth H Johnson; Monte Hunter; Jessica L Pierce; Kanglun Yu; Mark W Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2017-08-14       Impact factor: 6.741

7.  A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.

Authors:  Rachel K Surowiec; Lauren F Battle; Ferrous S Ward; Stephen H Schlecht; Basma M Khoury; Christopher Robbins; Edward M Wojtys; Michelle S Caird; Kenneth M Kozloff
Journal:  Bone       Date:  2019-10-31       Impact factor: 4.398

8.  Effects of Melandrium firmum Rohrbach on RANKL‑induced osteoclast differentiation and OVX rats.

Authors:  Minsun Kim; Jae-Hyun Kim; Sooyeon Hong; Boguen Kwon; Eun-Young Kim; Hyuk-Sang Jung; Youngjoo Sohn
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

9.  Solanum nigrum Line inhibits osteoclast differentiation and suppresses bone mineral density reduction in the ovariectomy‑induced osteoporosis model.

Authors:  Jae-Hyun Kim; Hwajeong Shin; Minsun Kim; Sangwoo Kim; Kwangchan Song; Hyuk-Sang Jung; Youngjoo Sohn
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

10.  CD109 plays a role in osteoclastogenesis.

Authors:  Yongqiang Wang; Maayan Inger; Hongwei Jiang; Howard Tenenbaum; Michael Glogauer
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.